The 13th annual ADMET conference is returning to London, UK for an in-depth exploration of the optimisation of ADMET modelling techniques, preclinical DMPK applications and the development of bioph
Sanofi is still plugging away with its oral BTK inhibitor tolebrutinib in multiple sclerosis, but has decided to abandon efforts to develop the drug for neuromuscular diso
In the newest episode of the pharmaphorum podcast, editor-in-chief Jonah Comstock speaks with Jameka Hill, senior director of clinical trial health equity at Moderna.
